Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) VP Theodore Alan Huizenga sold 1,338 shares of the company’s stock in a transaction that occurred on Wednesday, June 13th. The stock was sold at an average price of $76.97, for a total transaction of $102,985.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Ultragenyx Pharmaceutical stock traded up $3.47 during trading hours on Thursday, hitting $81.56. The company had a trading volume of 589,344 shares, compared to its average volume of 546,673. Ultragenyx Pharmaceutical Inc has a twelve month low of $41.67 and a twelve month high of $82.00. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of -10.53 and a beta of 1.97.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.81. The company had revenue of $10.68 million during the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the previous year, the company posted ($1.63) EPS. analysts expect that Ultragenyx Pharmaceutical Inc will post -5.32 earnings per share for the current year.
Several brokerages recently weighed in on RARE. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, May 26th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 19th. Barclays raised shares of Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $62.00 to $74.00 in a research report on Friday, May 11th. Goldman Sachs Group initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, May 10th. They issued a “neutral” rating and a $63.00 price objective on the stock. Finally, Cowen reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Ultragenyx Pharmaceutical presently has an average rating of “Buy” and a consensus price target of $70.06.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.